Addex Therapeutics (ADXN) Fundamental Analysis: Revenue, Earnings & Valuation

3.48 / 10

Netural

Fundamental breakdown reveals challenging profile (3.5/10). Supportive elements: Interest coverage ratio (EBIT / Interest expense) (%) and PB-ROE, but headwinds are noted in Asset-MV and Fixed assets turnover ratio. This suggests defensive positioning.

Analysis Checks(5/10)

ROA (%)

Value-54.32

Score1/3

Weight-2.40%

1M Return-0.21%

Total operating revenue (YoY growth rate %)

Value-61.56

Score2/3

Weight1.66%

1M Return0.14%

PB-ROE

Value0.32

Score2/3

Weight99.64%

1M Return7.01%

Income tax / Total profit (%)

Value-5.43

Score0/3

Weight-22.96%

1M Return-2.14%

Fixed assets turnover ratio

Value159.63

Score1/3

Weight-20.89%

1M Return-1.93%

Annualized net profit margin on total assets (%)

Value-72.43

Score1/3

Weight-2.40%

1M Return-0.21%

Interest coverage ratio (EBIT / Interest expense) (%)

Value15.64

Score2/3

Weight-13.03%

1M Return-1.16%

Operating revenue (YoY growth rate %)

Value-61.46

Score2/3

Weight4.76%

1M Return0.40%

Cost of sales ratio (%)

Value70.30

Score2/3

Weight-14.58%

1M Return-1.34%

Asset-MV

Value-0.49

Score1/3

Weight70.21%

1M Return5.15%

Is ADXN fundamentally strong?

ADXN scores 3.48/10 on fundamentals and holds a Fair valuation at present. Backed by its -62.56% ROE, -5123.22% net margin, -0.92 P/E ratio, 1.00 P/B ratio, and -265.56% earnings growth, these metrics solidify its Netural investment rating.